Thank you, Francesca. As a result, we are raising guidance ranges and for our full year 2024 total revenues and adjusted diluted earnings per share. Dave will discuss our continued work to reduce our ...

Polen 5Perspectives Small Growth Q4 2025 report reviews portfolio performance and sector trends. View the full commentary to ...

Good day, everyone, and welcome to Pfizer's Fourth Quarter 2025 Earnings Conference Call. Today's call is being recorded. At ...

The market for TIGIT inhibitors is expected to grow significantly in the coming years. This is due to the increasing number ...

In a multicenter, phase 2 trial across 31 centers in 10 countries, apecotrep (BI 764198) reduced proteinuria by 40% over 12 ...

Enzeevum, a biosimilar to Eylea, is approved in Canada for multiple retinal conditions, expanding treatment options for ophthalmologists. Biosimilars may offer cost-effective alternatives, potentially ...

This cat was born looking permanently unimpressed. Thanks to some wild fur markings, this cat appears to have thick eyebrows ...

Xbox has been having a hard time selling consoles lately, and it didn't get any better over the 2025 holiday quarter.

Boehringer Ingelheim has reported encouraging Phase II trial results for apecotrep (BI 764198), a potential first-in-class oral TRPC6 inhibitor being developed for primary focal segmental ...

Apecotrep (BI 764198) is a potential first-in-class, oral, selective TRPC6 inhibitor being investigated as a novel, targeted, non-immunosuppressive therapy in people with primary focal segmental ...

Not intended for the UK Apecotrep (BI 764198) is a potential first-in-class, oral, selective TRPC6 inhibitor being investigated as a novel, targeted, non-immunosuppressive therapy in people with prima ...

The Big Fix continues in line with Palazzo’s trend of presenting well-considered analysis regarding his adopted country’s ...